Semaglutide and tirzepatide recommended as first-line treatment of obesity and most of its complications in new guidance from European Association for the Study of Obesity (EASO) Semaglutide and tirzepatide recommended as first-line treatment of obesity and most of its complications in new guidance from European Association for the Study of Obesity (EASO) Research
Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity Policy, Research
Clinical Practice Guideline Support Disseminating Clinical Practice Guidelines for Obesity Dr. Cathy Breen, PhD, RD Health Service Executive, Ireland Watch now
